CG Oncology, Inc. Common stock (CGON NASDAQ) stock market data APIs
$37.7346
-0.95(-2.5%)
as of September 17, 2025
Try our APIs with
free plan!
CG Oncology, Inc. Common stock Financial Data Overview
Price chart is built with
Anychart
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Prev. Close
37.7346
Open
36.7828
High
38.7746
Low
35.5584
52 wk Range
14.8-40.47
Market Cap
2 876 M
Shares Outstanding
76 248 K
Revenue
551 K
EPS
-0.54
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with CG Oncology, Inc. Common stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CG Oncology, Inc. Common stock data using free add-ons & libraries
Get CG Oncology, Inc. Common stock Fundamental Data
CG Oncology, Inc. Common stock Fundamental data includes:
- Net Revenue: 551 K
- EBITDA: -157 088 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-08
- EPS/Forecast: -0.4422
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CG Oncology, Inc. Common stock News
New
CG Oncology (CGON) Reports Promising Results In BOND-003 Trial
CG Oncology recently reported promising developments from the BOND-003 trial with their investigational therapy, cretostimogene, showing significant efficacy in non-muscle invasive bladder cancer pati...
CG Oncology (CGON) Is Up 23.3% After 24-Month Complete Response Data in Phase 3 Bladder Cancer Study
CG Oncology recently released updated data from its Phase 3 BOND-003 Cohort C study, which showed a 41.8% 24-month complete response rate for cretostimogene monotherapy in heavily pretreated patients ...
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Ca...
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
CG Oncology Inc. - Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unrespons...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
